Khan Bilal Arshad 4

What Happened
Khan Bilal Arshad, an Outside Director of SpyGlass Pharma, was granted 13,700 shares (reported as a derivative award) on February 5, 2026. The award is reported at $0.00 per share (total reported value $0) and was recorded on a Form 4 filed February 9, 2026. This is an equity compensation award for board service — not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-05 (reported on Form 4 filed 2026-02-09). No late filing flag is indicated in the provided data.
• Transaction type/code: Award/Grant (A); 13,700 shares acquired, price reported $0.00.
• Ownership after transaction: Not specified in the provided filing.
• Footnote: Vesting is contingent on continuing service as an Outside Director. Per the plan footnote, 100% of the shares will vest on the earlier of (i) the one-year anniversary of the grant (Date of Grant = Feb 5, 2026) or (ii) immediately prior to the next annual meeting of stockholders.
• Nature: Derivative equity award (compensation), so no immediate cash outlay or sale occurred.

Context
This grant appears to be standard director compensation (equity subject to time-based vesting). For retail investors, such awards are common and do not by themselves indicate the director is buying or selling stock; they reflect incentive alignment that vests over time if the director remains in service.